- Home
- AKA vs INBX Comparison
AKA vs INBX Comparison
Compare AKA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | INBX |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.4M | 1.5B |
| IPO Year | 2021 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AKA | INBX |
|---|---|---|
| Price | $11.22 | $99.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $24.33 | ★ $150.00 |
| AVG Volume (30 Days) | 1.8K | ★ 309.3K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $600,208,000.00 | $1,300,000.00 |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 4.44 | ★ 550.00 |
| 52 Week Low | $8.42 | $28.16 |
| 52 Week High | $16.38 | $155.29 |
Technical Indicators
Market Signals| Indicator | AKA | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 57.61 | 41.24 |
| Support Level | $10.28 | $99.20 |
| Resistance Level | $11.69 | $106.40 |
| Average True Range (ATR) | 0.37 | 8.26 |
| MACD | 0.04 | -2.20 |
| Stochastic Oscillator | 97.37 | 16.95 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.